Titre :

Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.

Auteur(s) :

Maio, M. [Auteur]
Amonkar, M. M. [Auteur]
Norquist, J. M. [Auteur]
Ascierto, P. A. [Auteur]
Manzyuk, L. [Auteur]
Motola-Kuba, D. [Auteur]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Cassier, Philippe A. [Auteur]
Bariani, G. M. [Auteur]
De Jesus Acosta, A. [Auteur]
Doi, T. [Auteur]
Longo, F. [Auteur]
Miller, W. H. [Auteur]
Oh, D. Y. [Auteur]
Gottfried, M. [Auteur]
Wang, R. [Auteur]
Norwood, K. [Auteur]
Marabelle, Aurelien [Auteur]
Centre d'Investigation Clinique en Biotherapie des cancers [CIC 1428 , CBT 507 ]
Immunologie anti-tumorale et immunothérapie des cancers [ITIC]

Titre de la revue :

European Journal of Cancer

Nom court de la revue :

Eur J Cancer

Numéro :

169

Pagination :

188-197

Date de publication :

2022-05-20

ISSN :

1879-0852

Mot(s)-clé(s) en anglais :

Pembrolizumab
Health-related quality of life
Microsatellite instability

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability−high ...
Lire la suite >Background In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability−high (MSI-H)/mismatch repair‒deficient (dMMR) non-colorectal solid tumours. We present health-related quality of life (HRQoL) results from the MSI-H/dMMR population (cohort K). Patients and methods Eligible patients had previously treated MSI-H/dMMR advanced non-colorectal solid tumours, measurable disease per RECIST v1.1, and ECOG performance status ≤1. Patients received pembrolizumab 200 mg Q3W for 35 cycles (2 years). The EORTC Quality of Life Questionnaire (QLQ-C30) and EQ-5D-3L were administered at baseline, at regular intervals throughout treatment, and 30 days after treatment discontinuation. Prespecified analyses (exploratory endpoints) included the magnitude of change from baseline to post-baseline timepoints in all patients and by the best overall response for QLQ-C30 global health status (GHS)/QoL, QLQ-C30 functional/symptom scales/items, and EQ-5D-3L visual analogue scale (VAS) score. Results At data cutoff (October 5, 2020), 351 patients were enrolled, of whom 311 and 315 completed baseline QLQ-C30 and EQ-5D-3L questionnaires, respectively. QLQ-C30 GHS/QoL scores improved from baseline to week 9 (mean [95% CI] change, 3.07 [0.19–5.94]), then remained stable or improved by week 111, with greater improvements observed in patients with a best response of complete response (CR) or partial response (PR) (10.85 [6.36–15.35]). Patients with CR/PR showed improvements in physical (5.58 [1.91–9.25]), role (9.88 [3.80–15.97]), emotional (5.62 [1.56–9.68]), and social (8.33 [2.70–13.97]) functioning, and stable cognitive functioning (1.74 [−1.45 to 4.94]). Conclusions Pembrolizumab generally improved or preserved HRQoL in patients with previously treated MSI-H/dMMR advanced non-colorectal solid tumours.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T04:09:04Z
2024-05-13T13:09:47Z